Please use this identifier to cite or link to this item:
|Scopus||Web of Science®||Altmetric|
|Title:||The treatment of infertility in polycystic ovary syndrome: a brief update|
|Citation:||Australian and New Zealand Journal of Obstetrics and Gynaecology, 2012; 52(4):400-403|
|Publisher:||Blackwell Publishing Asia|
|Michael F. Costello, Marie L. Misso, Jennifer Wong, Roger Hart, Luk Rombauts, Angela Melder, Robert J. Norman and Helen J. Teede|
|Abstract:||Polycystic ovary syndrome (PCOS) is the most common cause of anovulatory infertility. Lifestyle change alone is considered the first-line treatment for the management of infertile anovulatory PCOS women who are overweight or obese. First-line medical ovulation induction therapy to improve fertility outcomes is clomiphene citrate, whilst gonadotrophins, laparoscopic ovarian surgery or possibly metformin are second line in clomiphene citrate-resistant PCOS women. There is currently insufficient evidence to recommend aromatase inhibitors over that of clomiphene citrate in infertile anovulatory PCOS women in general or specifically in therapy naive or clomiphene citrate-resistant PCOS women. IVF/ICSI treatment is recommended either as a third-line treatment or in the presence of other infertility factors.|
polycystic ovary syndrome
|Rights:||© 2012 The Authors ANZJOG © 2012 The Royal Australian and New Zealand College of Obstetricians and Gynaecologists|
|Appears in Collections:||Aurora harvest 5|
Medical Sciences publications
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.